Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Analysis & Investment Frameworks
Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) stock analysis on Invetso. Review Harrow Health, Inc. 11.875% Senior Notes due 2027’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Harrow Health, Inc. 11.875% Senior Notes due 2027 Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Harrow Health, Inc. 11.875% Senior Notes due 2027 Key Financial Metrics
- Market Cap: $1.34B
- Revenue: $272.30M
- ROE: -104.64%
- ROIC: -0.79%
- Dividend Yield: N/A
About Harrow Health, Inc. 11.875% Senior Notes due 2027
Harrow Health, Inc. focuses on the creation, production, and marketing of cutting-edge pharmaceutical solutions. Its business activities are primarily organized into two distinct divisions: Pharmaceutical Compounding and Pharmaceutical Drug Development. Specifically, the Pharmaceutical Compounding segment oversees the operations of the ImprimisRx enterprise. The company was established in January 2006 by Mark L. Baum and Robert J. Kammer, and its main corporate office is located in Nashville, Tennessee.